Mira Pharma reports Ketamir-2 beats Gabapentin and Pregabalin in preclinical neuropathic pain study

MIRA PHARMACEUTICALS, INC.

Ketamir-2 demonstrated significantly greater efficacy than FDA-approved Gabapentin (Neurontin) and Pregabalin (Lyrica) in preclinical neuropathic pain models.
IND application submission remains on track for end of 2024; Phase I trials expected to begin Q1 2025; Phase II by late 2025.
Exploring government funding opportunities to support planned PTSD clinical trials.
Additional preclinical studies focused on chemotherapy-induced and diabetic neuropathy are actively underway.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.